Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance

Wenmin Xia, Ariane R. Pessentheiner, Dina C. Hofer, Melina Amor, Renate Schreiber, Gabriele Schoiswohl, Thomas O. Eichmann, Evelyn Walenta, Bianca Itariu, Gerhard Prager, Hubert Hackl, Thomas Stulnig, Dagmar Kratky, Thomas Rülicke, Juliane G. Bogner-Strauss

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Elevated circulating fatty acids (FAs) contribute to obesity-associated metabolic complications, but the mechanisms by which insulin suppresses lipolysis are poorly understood. We show that α/β-hydrolase domain-containing 15 (ABHD15) is required for the anti-lipolytic action of insulin in white adipose tissue (WAT). Neither insulin nor glucose treatments can suppress FA mobilization in global and conditional Abhd15-knockout (KO) mice. Accordingly, insulin signaling is impaired in Abhd15-KO adipocytes, as indicated by reduced AKT phosphorylation, glucose uptake, and de novo lipogenesis. In vitro data reveal that ABHD15 associates with and stabilizes phosphodiesterase 3B (PDE3B). Accordingly, PDE3B expression is decreased in the WAT of Abhd15-KO mice, mechanistically explaining increased protein kinase A (PKA) activity, hormone-sensitive lipase (HSL) phosphorylation, and undiminished FA release upon insulin signaling. Ultimately, Abhd15-KO mice develop insulin resistance. Notably, ABHD15 expression is decreased in humans with obesity and diabetes compared to humans with obesity and normal glucose tolerance, identifying ABHD15 as a potential therapeutic target to mitigate insulin resistance. Xia et al. show that ABHD15 stabilizes PDE3B and, thereby, impacts the anti-lipolytic action of insulin. Loss of ABHD15 reduces PDE3B protein and leads to unrestrained fatty acid mobilization. Concomitantly, glucose uptake and de novo lipogenesis are reduced in Abhd15-knockout mice, which develop insulin resistance upon aging and dietary challenges.

LanguageEnglish
Pages1948-1961
Number of pages14
JournalCell Reports
Volume23
Issue number7
DOIs
StatusPublished - 15 May 2018

Fingerprint

Type 3 Cyclic Nucleotide Phosphodiesterases
Insulin Resistance
Insulin
Knockout Mice
Fatty Acids
Glucose
White Adipose Tissue
Lipogenesis
Obesity
Phosphorylation
Sterol Esterase
Lipolysis
Hydrolases
Cyclic AMP-Dependent Protein Kinases
Adipocytes
Tissue
Medical problems
Aging of materials

Keywords

  • ABHD15
  • adipose tissue
  • fatty acids
  • insulin resistance
  • lipolysis
  • PDE3B
  • type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance. / Xia, Wenmin; Pessentheiner, Ariane R.; Hofer, Dina C.; Amor, Melina; Schreiber, Renate; Schoiswohl, Gabriele; Eichmann, Thomas O.; Walenta, Evelyn; Itariu, Bianca; Prager, Gerhard; Hackl, Hubert; Stulnig, Thomas; Kratky, Dagmar; Rülicke, Thomas; Bogner-Strauss, Juliane G.

In: Cell Reports, Vol. 23, No. 7, 15.05.2018, p. 1948-1961.

Research output: Contribution to journalArticleResearchpeer-review

Xia, W, Pessentheiner, AR, Hofer, DC, Amor, M, Schreiber, R, Schoiswohl, G, Eichmann, TO, Walenta, E, Itariu, B, Prager, G, Hackl, H, Stulnig, T, Kratky, D, Rülicke, T & Bogner-Strauss, JG 2018, 'Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance', Cell Reports, vol. 23, no. 7, pp. 1948-1961. https://doi.org/10.1016/j.celrep.2018.04.055
Xia, Wenmin ; Pessentheiner, Ariane R. ; Hofer, Dina C. ; Amor, Melina ; Schreiber, Renate ; Schoiswohl, Gabriele ; Eichmann, Thomas O. ; Walenta, Evelyn ; Itariu, Bianca ; Prager, Gerhard ; Hackl, Hubert ; Stulnig, Thomas ; Kratky, Dagmar ; Rülicke, Thomas ; Bogner-Strauss, Juliane G. / Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance. In: Cell Reports. 2018 ; Vol. 23, No. 7. pp. 1948-1961.
@article{9f4f960d593f455bbdb0b65021dabb36,
title = "Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance",
abstract = "Elevated circulating fatty acids (FAs) contribute to obesity-associated metabolic complications, but the mechanisms by which insulin suppresses lipolysis are poorly understood. We show that α/β-hydrolase domain-containing 15 (ABHD15) is required for the anti-lipolytic action of insulin in white adipose tissue (WAT). Neither insulin nor glucose treatments can suppress FA mobilization in global and conditional Abhd15-knockout (KO) mice. Accordingly, insulin signaling is impaired in Abhd15-KO adipocytes, as indicated by reduced AKT phosphorylation, glucose uptake, and de novo lipogenesis. In vitro data reveal that ABHD15 associates with and stabilizes phosphodiesterase 3B (PDE3B). Accordingly, PDE3B expression is decreased in the WAT of Abhd15-KO mice, mechanistically explaining increased protein kinase A (PKA) activity, hormone-sensitive lipase (HSL) phosphorylation, and undiminished FA release upon insulin signaling. Ultimately, Abhd15-KO mice develop insulin resistance. Notably, ABHD15 expression is decreased in humans with obesity and diabetes compared to humans with obesity and normal glucose tolerance, identifying ABHD15 as a potential therapeutic target to mitigate insulin resistance. Xia et al. show that ABHD15 stabilizes PDE3B and, thereby, impacts the anti-lipolytic action of insulin. Loss of ABHD15 reduces PDE3B protein and leads to unrestrained fatty acid mobilization. Concomitantly, glucose uptake and de novo lipogenesis are reduced in Abhd15-knockout mice, which develop insulin resistance upon aging and dietary challenges.",
keywords = "ABHD15, adipose tissue, fatty acids, insulin resistance, lipolysis, PDE3B, type 2 diabetes",
author = "Wenmin Xia and Pessentheiner, {Ariane R.} and Hofer, {Dina C.} and Melina Amor and Renate Schreiber and Gabriele Schoiswohl and Eichmann, {Thomas O.} and Evelyn Walenta and Bianca Itariu and Gerhard Prager and Hubert Hackl and Thomas Stulnig and Dagmar Kratky and Thomas R{\"u}licke and Bogner-Strauss, {Juliane G.}",
year = "2018",
month = "5",
day = "15",
doi = "10.1016/j.celrep.2018.04.055",
language = "English",
volume = "23",
pages = "1948--1961",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance

AU - Xia, Wenmin

AU - Pessentheiner, Ariane R.

AU - Hofer, Dina C.

AU - Amor, Melina

AU - Schreiber, Renate

AU - Schoiswohl, Gabriele

AU - Eichmann, Thomas O.

AU - Walenta, Evelyn

AU - Itariu, Bianca

AU - Prager, Gerhard

AU - Hackl, Hubert

AU - Stulnig, Thomas

AU - Kratky, Dagmar

AU - Rülicke, Thomas

AU - Bogner-Strauss, Juliane G.

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Elevated circulating fatty acids (FAs) contribute to obesity-associated metabolic complications, but the mechanisms by which insulin suppresses lipolysis are poorly understood. We show that α/β-hydrolase domain-containing 15 (ABHD15) is required for the anti-lipolytic action of insulin in white adipose tissue (WAT). Neither insulin nor glucose treatments can suppress FA mobilization in global and conditional Abhd15-knockout (KO) mice. Accordingly, insulin signaling is impaired in Abhd15-KO adipocytes, as indicated by reduced AKT phosphorylation, glucose uptake, and de novo lipogenesis. In vitro data reveal that ABHD15 associates with and stabilizes phosphodiesterase 3B (PDE3B). Accordingly, PDE3B expression is decreased in the WAT of Abhd15-KO mice, mechanistically explaining increased protein kinase A (PKA) activity, hormone-sensitive lipase (HSL) phosphorylation, and undiminished FA release upon insulin signaling. Ultimately, Abhd15-KO mice develop insulin resistance. Notably, ABHD15 expression is decreased in humans with obesity and diabetes compared to humans with obesity and normal glucose tolerance, identifying ABHD15 as a potential therapeutic target to mitigate insulin resistance. Xia et al. show that ABHD15 stabilizes PDE3B and, thereby, impacts the anti-lipolytic action of insulin. Loss of ABHD15 reduces PDE3B protein and leads to unrestrained fatty acid mobilization. Concomitantly, glucose uptake and de novo lipogenesis are reduced in Abhd15-knockout mice, which develop insulin resistance upon aging and dietary challenges.

AB - Elevated circulating fatty acids (FAs) contribute to obesity-associated metabolic complications, but the mechanisms by which insulin suppresses lipolysis are poorly understood. We show that α/β-hydrolase domain-containing 15 (ABHD15) is required for the anti-lipolytic action of insulin in white adipose tissue (WAT). Neither insulin nor glucose treatments can suppress FA mobilization in global and conditional Abhd15-knockout (KO) mice. Accordingly, insulin signaling is impaired in Abhd15-KO adipocytes, as indicated by reduced AKT phosphorylation, glucose uptake, and de novo lipogenesis. In vitro data reveal that ABHD15 associates with and stabilizes phosphodiesterase 3B (PDE3B). Accordingly, PDE3B expression is decreased in the WAT of Abhd15-KO mice, mechanistically explaining increased protein kinase A (PKA) activity, hormone-sensitive lipase (HSL) phosphorylation, and undiminished FA release upon insulin signaling. Ultimately, Abhd15-KO mice develop insulin resistance. Notably, ABHD15 expression is decreased in humans with obesity and diabetes compared to humans with obesity and normal glucose tolerance, identifying ABHD15 as a potential therapeutic target to mitigate insulin resistance. Xia et al. show that ABHD15 stabilizes PDE3B and, thereby, impacts the anti-lipolytic action of insulin. Loss of ABHD15 reduces PDE3B protein and leads to unrestrained fatty acid mobilization. Concomitantly, glucose uptake and de novo lipogenesis are reduced in Abhd15-knockout mice, which develop insulin resistance upon aging and dietary challenges.

KW - ABHD15

KW - adipose tissue

KW - fatty acids

KW - insulin resistance

KW - lipolysis

KW - PDE3B

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85046834078&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.04.055

DO - 10.1016/j.celrep.2018.04.055

M3 - Article

VL - 23

SP - 1948

EP - 1961

JO - Cell Reports

T2 - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 7

ER -